Maggie Tibbitt


Upifitamab Rilsodotin May Answer Questions in Platinum-Resistant Recurrent Ovarian Cancer

February 02, 2022

An expert from Arizona Oncology discusses the unmet need for agents to address recurrent ovarian cancer and how upifitamab rilsodotin, an antibody-drug conjugate with promising preclinical and clinical data, may play into the treatment paradigm.